ATRA
Price
$12.91
Change
+$0.11 (+0.86%)
Updated
Sep 5 closing price
Capitalization
90.67M
NGENF
Price
$2.73
Change
+$0.18 (+7.06%)
Updated
Sep 5 closing price
Capitalization
200.8M
Interact to see
Advertisement

ATRA vs NGENF

Header iconATRA vs NGENF Comparison
Open Charts ATRA vs NGENFBanner chart's image
Atara Biotherapeutics
Price$12.91
Change+$0.11 (+0.86%)
Volume$65.66K
Capitalization90.67M
NervGen Pharma
Price$2.73
Change+$0.18 (+7.06%)
Volume$35.29K
Capitalization200.8M
ATRA vs NGENF Comparison Chart in %
Loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATRA vs. NGENF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a StrongBuy and NGENF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ATRA: $12.91 vs. NGENF: $2.73)
Brand notoriety: ATRA and NGENF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 123% vs. NGENF: 36%
Market capitalization -- ATRA: $90.67M vs. NGENF: $200.8M
ATRA [@Biotechnology] is valued at $90.67M. NGENF’s [@Biotechnology] market capitalization is $200.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileNGENF’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • NGENF’s FA Score: 0 green, 5 red.
According to our system of comparison, ATRA is a better buy in the long-term than NGENF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 4 TA indicator(s) are bullish while NGENF’s TA Score has 6 bullish TA indicator(s).

  • ATRA’s TA Score: 4 bullish, 2 bearish.
  • NGENF’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ATRA and NGENF are a good buy in the short-term.

Price Growth

ATRA (@Biotechnology) experienced а +7.14% price change this week, while NGENF (@Biotechnology) price change was +2.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NGENF($201M) has a higher market cap than ATRA($90.7M). NGENF YTD gains are higher at: 25.229 vs. ATRA (-3.005). ATRA has higher annual earnings (EBITDA): 14.3M vs. NGENF (-25.94M). ATRA has more cash in the bank: 22.3M vs. NGENF (14.6M). NGENF has less debt than ATRA: NGENF (81.8K) vs ATRA (17.7M). ATRA has higher revenues than NGENF: ATRA (189M) vs NGENF (0).
ATRANGENFATRA / NGENF
Capitalization90.7M201M45%
EBITDA14.3M-25.94M-55%
Gain YTD-3.00525.229-12%
P/E Ratio17.93N/A-
Revenue189M0-
Total Cash22.3M14.6M153%
Total Debt17.7M81.8K21,638%
FUNDAMENTALS RATINGS
ATRA vs NGENF: Fundamental Ratings
ATRA
NGENF
OUTLOOK RATING
1..100
237
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
10064
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3846
P/E GROWTH RATING
1..100
35100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATRA's Valuation (75) in the Biotechnology industry is in the same range as NGENF (96) in the null industry. This means that ATRA’s stock grew similarly to NGENF’s over the last 12 months.

NGENF's Profit vs Risk Rating (64) in the null industry is somewhat better than the same rating for ATRA (100) in the Biotechnology industry. This means that NGENF’s stock grew somewhat faster than ATRA’s over the last 12 months.

NGENF's SMR Rating (100) in the null industry is in the same range as ATRA (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to ATRA’s over the last 12 months.

ATRA's Price Growth Rating (38) in the Biotechnology industry is in the same range as NGENF (46) in the null industry. This means that ATRA’s stock grew similarly to NGENF’s over the last 12 months.

ATRA's P/E Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for NGENF (100) in the null industry. This means that ATRA’s stock grew somewhat faster than NGENF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRANGENF
RSI
ODDS (%)
Bearish Trend 5 days ago
88%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 13 days ago
83%
Declines
ODDS (%)
Bearish Trend 27 days ago
87%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANOYX24.97N/A
N/A
American Century Small Cap Growth Y
RPNRX13.83N/A
N/A
RiverPark/Next Century Lg Gr Retl
FHKIX48.32N/A
N/A
Fidelity Advisor China Region I
GIRVX8.11N/A
N/A
Goldman Sachs Intl Eq Div & Prem Inv
IIGZX12.53N/A
N/A
Voya Global High Dividend Low Vol Port I

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with ABCZF. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then ABCZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
+0.86%
ABCZF - ATRA
53%
Loosely correlated
N/A
RAPT - ATRA
37%
Loosely correlated
+1.57%
PHAT - ATRA
36%
Loosely correlated
+2.83%
INVA - ATRA
33%
Poorly correlated
-2.10%
SRRK - ATRA
32%
Poorly correlated
-3.18%
More

NGENF and

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
+7.06%
CYTK - NGENF
25%
Poorly correlated
+6.55%
IBRX - NGENF
23%
Poorly correlated
+0.42%
TNFA - NGENF
22%
Poorly correlated
-8.59%
CARM - NGENF
22%
Poorly correlated
+25.59%
ATRA - NGENF
22%
Poorly correlated
+0.86%
More